Search results for "TKIs"
showing 9 items of 9 documents
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
2020
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The discovery of the EML4-ALK fusion gene in a limited subset of patients affected by NSCLC and the subsequent clinical development of crizotinib in 2011 has been an impressive milestone in lung cancer research. Unfortunately, acquired resistances regularly develop, hence disease progression occurs. Afterward, modern tyrosine kinase inhibitors (TKIs), such as ceritinib, alectinib, brigatinib, and lorlat…
EGFR inhibition in NSCLC: New findings…. and opened questions?
2017
The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent f…
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
2021
Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the last years due to development and clinical approval of highly effective agents including immune checkpoint inhibitors (ICIs) and oncogene-directed therapies. Molecular profiling of lung cancer samples for activated oncogenes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and BRAF, is routinely performed to select the most appropriate up-front treatment. However, the identification of new therapeutic targets remains a high priority. Recently, MET exon 14 skipping mutations have emerged as novel actionable oncogenic alterations in NSCLC, sensiti…
Ernesta Foldāta vēstule draugiem LU Bioloģijas fakultātē 1995. gada 8. augustā
1995
Ernesta Foldāta vēstule draugiem Latvijas Universitātes Bioloģijas fakultātē, kurā viņš raksta par profesoru Edgaru Rutki un viņas sievas slimību un nāvi, savas ģimenes locekļu veselības stāvokļiem, grūto ekonomisko stāvokli Venecuēlā, dēlu grūtībām uzņēmuma vadīšanā, savu grāmatu izdošanu. Beigās novēlējumi un paraksts. Kopija vēstulei, kas drukāta mašīnrakstā uz vienas lapas. Glabājas Latvijas Universitātes Muzeja Botānikas un mikoloģijas kolekciju krājumā.
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?
2014
Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal-epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpr…
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform
2019
Background/Aim: The Philadelphia chromosome is the most frequent cytogenetic abnormality in chronic myelogenous (CML). More than 95% of CML patients are diagnosed with the e13a2 or e14a2 BCR-ABL1 fusion transcripts while, in about 1% of these individuals, the break generates the e1a2 rearrangement. Furthermore, about 5% of CML patients are diagnosed with rare BCR-ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3 and e6a2. However, there is limited evidence concerning the clinical and prognostic implications of these infrequent oncogenic variants for CML patients receiving tyrosine kinase inhibitors (TKIs). Case Report: We describe a novel atypical e12a2 insertion/deletion (In…
The story of Pitkis-Sport in Satakunnan kansa : content analysis of newspaper articles on a children and youth sports camp
2014
This study examines the media publicity of Pitkis-Sport, a children and youth sports camp, in Satakunnan Kansa, a regional newspaper. The representations of Pitkis-Sport in the paper during the camp’s 50 years of history from 1963 to 2013 will be explored by using qualitative content analysis. Furthermore, changes in the coverage between the decades will be highlighted. The study aims to find out more about how child and youth sports and physical activities are reported in Finnish regional newspapers. In addition, a quantitative table of published articles and photos is compiled and compared with the amounts of camp participants. The aim is to give insights for the future on how sport journ…
Symbolit harrastajataiteessa
2000
Puukuitususpension putkistovirtaus, viskositeetti ja häviökorrelaatiomalli
2010
We measured pressure loss and velocity profile from pine and birch suspension flow in two straight PVC-tubes. The suspension consistencies were 0,5 %–4,0 % and tubes' radius were 105,2 mm and 191,6 mm. The velocity profiles were measured with pulsed ultrasonic Doppler velocimetry technique. Unusual laminar shaped profiles were discovered at low flow rates of birch suspension. With these profiles it was possible to calculate the actual viscosity for fiber suspension. In the analysis we discovered that the viscosity didn't depend on the flow velocity or geometry. It was possible to write a material law that describes the viscosity as a function of shear rate with two material related paramete…